Patents by Inventor Seong Hoe Park

Seong Hoe Park has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody that binds domain 2 of ICAM-1 and methods of treatment
    Patent number: 9334326
    Abstract: Disclosed are a monoclonal antibody targeting domain 2 of ICAM-1 protein and a composition comprising the monoclonal antibody for treating or preventing T cell-mediated immune disease. The antibody of the present application induces antigen-specific T cell tolerance through the regulation of dendritic cell differentiation, and therefore, can be effectively used to treat or prevent autoimmune disease, organ or tissue transplant rejection, and graft-versus-host-disease.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: May 10, 2016
    Assignee: SNU R&DB FOUNDATION
    Inventors: Seong Hoe Park, Kyeong Cheon Jung
  • ICAM-1 ANTIBODY AND USE THEREOF
    Publication number: 20150252111
    Abstract: Disclosed are a monoclonal antibody targeting domain 2 of ICAM-1 protein and a composition comprising the monoclonal antibody for treating or preventing T cell-mediated immune disease. The antibody of the present application induces antigen-specific T cell tolerance through the regulation of dendritic cell differentiation, and therefore, can be effectively used to treat or prevent autoimmune disease, organ or tissue transplant rejection, and graft-versus-host-disease.
    Type: Application
    Filed: October 11, 2012
    Publication date: September 10, 2015
    Applicant: SNU R&DB FOUNDATION
    Inventors: Seong Hoe Park, Kyeong Cheon Jung
  • Antibody that binds domain 2 of ICAM-1 and methods of treatment
    Patent number: 8900586
    Abstract: The present invention relates to an antibody binding to the domain 2 of human intercellular adhesion molecules-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and induce antigen-specific T cell tolerance, thereby be effective in the prevention and/or treatment of T cell-mediated immune disorders such as transplantation rejection, graft-versus-host disease, and autoimmune disease. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease.
    Type: Grant
    Filed: July 5, 2011
    Date of Patent: December 2, 2014
    Assignees: Dinona Inc., SNU R&DB Foundation
    Inventors: Seong Hoe Park, Kyeong Cheon Jung
  • ANTIBODY INDUCING ANTIGEN-SPECIFIC T CELL TOLERANCE AND USE THEREOF
    Publication number: 20140148583
    Abstract: The present invention relates to an antibody binding to the domain 2 of human intercellular adhesion molecules-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and induce antigen-specific T cell tolerance, thereby be effective in the prevention and/or treatment of T cell-mediated immune disorders such as transplantation rejection, graft-versus-host disease, and autoimmune disease. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease.
    Type: Application
    Filed: July 5, 2011
    Publication date: May 29, 2014
    Applicants: SNU R&DB FOUNDATION, DINONA INC.
    Inventors: Seong Hoe Park, Kyeong Cheon Jung
  • Cell surface protein expressed on human cortical thymocyte and their use
    Patent number: 6225286
    Abstract: A novel protein which is glycoprotein with 120,000 molecular weight and is expressed T lymphoblastic lymphoma and leukemia cells, is useful in the diagnosis of T lymphoblastic lymphoma and leukemia.
    Type: Grant
    Filed: April 1, 1999
    Date of Patent: May 1, 2001
    Inventors: Seong Hoe Park, Young Mee Bae
  • Cell surface protein expressed on human cortical thymocyte and their use
    Patent number: 5942404
    Abstract: A novel protein which is glycoprotein with 120,000 molecular weight and is expressed on T lymphoblastic lymphoma and leukemia cells, is useful in the diagnosis of T lymphoblastic lymphoma and leukemia.
    Type: Grant
    Filed: September 25, 1997
    Date of Patent: August 24, 1999
    Assignee: Seong Hoe Park
    Inventors: Seong Hoe Park, Young Mee Bae
  • Cell surface protein expressed on human cortical thymocyte and their use
    Patent number: 5879911
    Abstract: A novel protein which is glycoprotein with 120,000 molecular weight and is expressed on T lymphoblastic lymphoma and leukemia cells, is useful in the diagnosis of T lymphoblastic lymphoma and leukemia.
    Type: Grant
    Filed: January 15, 1997
    Date of Patent: March 9, 1999
    Assignee: Seong Hoe Park
    Inventors: Seong Hoe Park, Young Mee Bae
  • Cell surface protein JL-1 expressed on human cortical thymocyte and its use
    Patent number: 5641860
    Abstract: A novel isolated protein which is glycoprotein with 120,000 molecular weight and is expressed on T lymphoblastic lymphoma and leukemia cells, is useful in the diagnosis of T lymphoblastic lymphoma and leukemia.
    Type: Grant
    Filed: May 23, 1994
    Date of Patent: June 24, 1997
    Assignee: Seong Hoe Park
    Inventors: Seong Hoe Park, Young Mee Bae